11 June 2020 - Sean Lybrand and I reviewed the Pharmaceutical Benefits Advisory Committee submissions and their related outcomes and timelines since 2010.

We saw an increase in the annual number of submissions (medicine/patient population parings). The recommendation rate for the study period was higher than the rejection rate. 

The annual mean value for the period from the date of initial PBAC recommendation to the date of PBS listing ranged from 357 to 644 days; the annual mean value for the period of the date of PBAC recommendation to the date of PBS listing ranged from 187 to 245 days.

Read International Journal of Technology Assessment in Health Care article